On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...
Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its depression therapy Spravato (esketamine), expanding its use as a single agent ...
However, Johnson & Johnson has a 'savior' in its neuroscience portfolio, namely Spravato (esketamine), which is the NMDA receptor antagonist. Moreover, on January 21, 2025, the FDA approved ...
Credit: Johnson & Johnson. The approval of Spravato ... The Food and Drug Administration (FDA) has approved Spravato ® (esketamine) nasal spray for use as monotherapy for patients with treatment ...
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...